Study: Insulin payment strategy could reduce costs for insurers, patients

A new study adds to a growing body of literature suggesting that human insulins may result in similar clinical outcomes as higher cost insulin analogues for many patients with type 2 diabetes, according to a report last week in JAMA. The study looked at an initiative implemented by a Medicare Advantage plan to encourage members with diabetes to switch from insulin analogue to human insulin. The program was associated with a small increase in population-level HbA1C, but no significant change in rates of serious hypoglycemia or hyperglycemia. Human insulin use increased to 70 percent of insulin prescriptions over the three-year initiative, while overall expenditures for insulin decreased by more than 50 percent.
Related News Articles
Headline
The AHA July 16 announced five winners of the 2025 AHA Dick Davidson NOVA Award for their hospital-led collaborative efforts to improve community…
Headline
The Centers for Medicare & Medicaid Services June 27 announced the rollout of a 6-year technology-enabled prior authorization program pilot. Through…
Headline
AHA podcast: Food as Medicine — How Cleveland Clinic Is Nourishing Community HealthVickie Johnson, executive vice president and chief community officer at…
Headline
As part of Community Health Improvement Week June 9-13, two experts from Corewell Health share how an impactful health care ecosystem model is supporting local…
Headline
With June 9-13 being Community Health Improvement Week, three experts from HonorHealth discuss how the health care network is addressing community needs beyond…
Blog
Even before the COVID pandemic, the mental health and wellness of our young people was failing. The pandemic exacerbated the crisis and made it difficult for…